Unexpected drug-induced renal toxicity is one of the leading causes of failure in drug development programs. Researchers have been limited to the use of biomarkers that lack the sensitivity necessary to identify damage before it becomes permanent. In conjunction with the Predictive Safety Testing Consortium (PSTC) and our biopharmaceutical partners, Myriad RBM has developed renal toxicity biomarker panels that provide comprehensive, sensitive and quantitative measurement in rat, primate and non-human primate animal models. Myriad RBM’s Human KidneyMAP and BioPlex Pro™ RBM Rat Kidney Toxicity services allow drug developers to efficiently monitor kidney damage in order to prioritize medicinal chemistry programs, accelerate decisions on pre-clinical and early-stage clinical trial results, and confidently advance programs into late-stage development.